ReviewCardiology in review
Chagas heart disease: report on recent developments.
Review in Cardiology in review. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2023Pooled it
- The burden of zoonoses in Paraguay: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.The Cochrane database of systematic reviews · 2016 · on this mapPooled it
- Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial.Trials · 2014Trial
- The Biological Significance of Trogocytosis.Results and problems in cell differentiation · 2024Article
- Five-year serological and clinical evolution of chronic Chagas disease patients in Cochabamba, Bolivia.PLoS neglected tropical diseases · 2023Observational
- Main Cardiac Histopathologic Alterations in the Acute Phase ofPathogens (Basel, Switzerland) · 2023Article
- Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Cardiomyocyte infection byFrontiers in cellular and infection microbiology · 2023Article
- Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure.Journal of clinical medicine · 2022Review
- Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ.Frontiers in immunology · 2021Article
- Galectins in Chagas Disease: A Missing Link BetweenFrontiers in microbiology · 2021Review
- Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients.The American journal of tropical medicine and hygiene · 2020Article
- Article
- Article
- Echocardiographic Findings in Canine Model of Chagas Disease Immunized with DNAAnimals : an open access journal from MDPI · 2020Article
- DNA Vaccine Treatment in Dogs Experimentally Infected withJournal of immunology research · 2020Article
- Although with intact mucosa at colonoscopy, chagasic megacolons have an overexpression of Gal-3.Einstein (Sao Paulo, Brazil) · 2020Article
- Rapamycin Treatment Reduces Acute Myocarditis Induced by Trypanosoma cruzi Infection.Journal of innate immunity · 2020Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 3 countries.
Funding
Abstract
Chagas disease, caused by the parasite Trypanosoma cruzi, is an important cause of cardiac disease in endemic areas of Latin America. It is now being diagnosed in nonendemic areas because of immigration. Typical cardiac manifestations of Chagas disease include dilated cardiomyopathy, congestive heart failure, arrhythmias, cardioembolism, and stroke. Clinical and laboratory-based research to define the pathology resulting from T. cruzi infection has shed light on many of the cellular and molecular mechanisms leading to these manifestations. Antiparasitic treatment may not be appropriate for patients with advanced cardiac disease. Clinical management of Chagas heart disease is similar to that used for cardiomyopathies caused by other processes. Cardiac transplantation has been successfully performed in a small number of patients with Chagas heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.